NKP-1339|NKP-1339|ruthenium-based anticancer drug

NKP-1339|NKP-1339|ruthenium-based anticancer drug

NKP-1339 is the first-in-class ruthenium-based anticancer drug in clinical development against solid cancer and has recently been studied successfully in a phase I clinical trial.

Product Name: NKP-1339|Cat No. DC9786|CAS: 197723-00-5|Other names:KP1339,KP 1339,NKP1339,NKP 1339,KP-1339|MW: 502.14|Molecule Formular: C14H12Cl4N4NaRu|Purity>98%